Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-2

Learn More

Alibaba Cloud, Fintech Academy and Pfizer Partner to Accelerate Healthcare Innovations

LEARN MORE

RECENT PRESS RELEASES

11/02/2020 - XTANDI® (enzalutamide) Demonstrates Significant Improvement in Overall Survival in Phase 3 PROSPER Trial of Patients with nmCRPC
31/01/2020 - Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE™ (rituximab)
28/01/2020 - PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 RESULTS
23/01/2020 - Pfizer Vaccines Launches Global Centers of Excellence Network to Conduct Real-World Research on Vaccine-Preventable Diseases Affecting Adults
23/01/2020 - PFIZER’S GREENSTONE AND DIGITAL MEN’S HEALTH CLINIC ROMAN COLLABORATE TO OFFER PATIENTS REMOTE ACCESS TO THE ONLY FDA-APPROVED AUTHORIZED GENERIC VERSION OF VIAGRA® (SILDENAFIL CITRATE)
06/01/2020 - BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma